Page 49 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine EZH2 inhibition in ARID1A-deficient TNBC

breast cancer: Therapeutic Implications for tumor 27. Hirukawa A, Smith HW, Zuo D, et al. Targeting EZH2
microenvironment. Pharmacol Res. 2024;204:107205. reactivates a breast cancer subtype-specific anti-metastatic
transcriptional program. Nat Commun. 2018;9(1):2547.
doi: 10.1016/j.phrs.2024.107205
doi: 10.1038/s41467-018-04864-8
17. Wu F, Li N, Wu X, et al. EZH2 mutation is associated
with the development of visceral metastasis by enhancing 28. Borkiewicz L. Histone 3 lysine 27 trimethylation signature
proliferation and invasion and inhibiting apoptosis in breast in breast cancer. Int J Mol Sci. 2021;22(23):12853.
cancer cells. BMC Cancer. 2024;24(1):1166. doi: 10.3390/ijms222312853
doi: 10.1186/s12885-024-12950-y 29. Gong C, Yao S, Gomes AR, et al. BRCA1 positively regulates
18. Glancy E, Wang C, Tuck E, et al. PRC2.1-and PRC2.2-specific FOXO3 expression by restricting FOXO3 gene methylation
accessory proteins drive recruitment of different forms of and epigenetic silencing through targeting EZH2 in breast
canonical PRC1. Mol Cell. 2023;83(9):1393-1411.e7. cancer. Oncogenesis. 2016;5(4):e214.
doi: 10.1016/j.molcel.2023.03.018 doi: 10.1038/oncsis.2016.23
19. Singh V, Nandi S, Ghosh A, et al. Epigenetic reprogramming 30. Yang X, Karuturi RK, Sun F, et al. CDKN1C (P57) is
of T cells: Unlocking new avenues for cancer immunotherapy. a direct target of EZH2 and suppressed by multiple
Cancer Metastasis Rev. 2024;43:175-195. epigenetic mechanisms in breast cancer cells. PLoS One.
2009;4(4):e5011.
doi: 10.1007/s10555-024-10167-w
doi: 10.1371/journal.pone.0005011
20. Alldredge JK, Eskander RN. EZH2 inhibition in ARID1A
mutated clear cell and endometrioid ovarian and 31. Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2
endometrioid endometrial cancers. Gynecol Oncol Res Pract. regulates tumor invasion via the transcriptional repression
2017;4:17. of the metastasis suppressor RKIP in breast and prostate
cancer. Cancer Res. 2012;72(12):3091-3104.
doi: 10.1186/s40661-017-0052-y
doi: 10.1158/0008-5472.Can-11-3546
21. Bitler BG, Aird KM, Garipov A, et al. Synthetic lethality
by targeting EZH2 methyltransferase activity in arid1a- 32. Zhang R, Li X, Liu Z, Wang Y, Zhang H, Xu H. EZH2
mutated cancers. Nat Med. 2015;21(3):231-238. inhibitors-mediated epigenetic reactivation of fosb inhibits
triple-negative breast cancer progress. Cancer Cell Int.
doi: 10.1038/nm.3799 2020;20:175.
22. Chien YC, Liu LC, Ye HY, Wu JY, Yu YL. EZH2 promotes doi: 10.1186/s12935-020-01260-5
migration and invasion of triple-negative breast cancer cells
via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res. 33. Zheng XJ, Li W, Yi J, et al. EZH2 regulates expression of
2018;8(3):422-434. FOXC1 by mediating H3K27me3 in breast cancers. Acta
Pharmacol Sin. 2021;42(7):1171-1179.
23. Hussein YR, Sood AK, Bandyopadhyay S, et al. Clinical and
biological relevance of enhancer of zeste homolog 2 in triple- doi: 10.1038/s41401-020-00543-x
negative breast cancer. Hum Pathol. 2012;43(10):1638-1644. 34. Lu Y, Gu F, Ma Y, et al. Simultaneous delivery of doxorubicin
doi: 10.1016/j.humpath.2011.12.004 and EZH2-targeting sirna by vortex magnetic nanorods
synergistically improved anti-tumor efficacy in triple-
24. Gonzalez ME, Naimo GD, Anwar T, et al. EZH2 T367 negative breast cancer. Small. 2023;19(43):e2301307.
phosphorylation activates P38 signaling through lysine
methylation to promote breast cancer progression. iScience. doi: 10.1002/smll.202301307
2022;25(8):104827. 35. Verma A, Singh A, Singh MP, et al. EZH2-H3K27me3
doi: 10.1016/j.isci.2022.104827 mediated KRT14 upregulation promotes tnbc peritoneal
metastasis. Nat Commun. 2022;13(1):7344.
25. Gonzalez-Crespo I, Gomez-Caamano A, Pouso OL,
Fenwick JD, Pardo-Montero J. A biomathematical model doi: 10.1038/s41467-022-35059-x
of tumor response to radioimmunotherapy with αPDL1 36. Lawrence CL, Baldwin AS. Non-canonical EZH2
and αCTLA4. IEEE/ACM Trans Comput Biol Bioinform. transcriptionally activates relb in triple negative breast
2023;20(2):808-821. cancer. PLoS One. 2016;11(10):e0165005.
doi: 10.1109/tcbb.2022.3174454 doi: 10.1371/journal.pone.0165005
26. Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 37. Lee ST, Li Z, Wu Z, et al. Context-specific regulation of
2 (EZH2) down-regulates RUNX3 by increasing histone H3 NF-ΚB target gene expression by EZH2 in breast cancers.
methylation. J Biol Chem. 2008;283(25):17324-17332. Mol Cell. 2011;43(5):798-810.
doi: 10.1074/jbc.M800224200 doi: 10.1016/j.molcel.2011.08.011

Volume 3 Issue 1 (2025) 41 doi: 10.36922/arnm.5132